Clinical Trial

Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2024 (before its estimated April 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of cadonilimab combined with chemotherapy in patients with resectable IB (≥ 4cm) - IIIB (N2) stage PD-L1 negative non-small cell lung cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-29.
Status change: Not Yet Recruiting → Recruiting 2024-12-18
Trial Details
NCT Number NCT06532591
Lead Sponsor Sichuan Cancer Hospital and Research Institute
Conditions NSCLC
Enrollment 20 participants
Start Date 2024-08-01
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-20